D5W

Phase 2Small molecule

TThe University of Texas Health Science Center at San Antonio

D5W is one of 107 small molecule programs targeting Insulin resistance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Renal ColicActive, not recruiting

Patent Ductus ArteriosusActive, not recruiting

Septic ShockActive, not recruiting

Insulin ResistancePhase 2

Active, not recruiting

Renal ColicPreclinical

Active, not recruiting

Patent Ductus ArteriosusPhase 2

Active, not recruiting

Septic ShockPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

D5W

TThe University of Texas Health Science Center at San Antonio

Phase 2

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 8

Glucophage

EMD Serono

Preclinical

1 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Avastin

BBio-Thera Solutions

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Colic1 trial

Efficacy of Magnesium Sulfate on Reducing Renal Colic in the Emergency Department

Completed·HHenry Ford Health System·N/A·NCT03617289·37 enrolled

Obese1 trial

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02267317·15 enrolled

Patent ductus arteriosus1 trial

Paracetamol and Patent Ductus Arteriosus (PDA)

Unknown status·SShaare Zedek Medical Center·Phase 2·NCT01291654·80 enrolled

Septic Shock1 trial

Thiamine as a Metabolic Resuscitator in Septic Shock

Completed·—·Phase 1/2·NCT01070810·88 enrolled

Insulin resistance1 trial

The Role of TLR4 on Lipid-induced Insulin Resistance

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02321111·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for D5W. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D5W compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D5W. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center at San Antonio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe University of Texas Health Science Center at San Antonio

D5W

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Colic1 trial

Obese1 trial

Patent ductus arteriosus1 trial

Septic Shock1 trial

Insulin resistance1 trial

References

Drug Info

Quick Facts

Related News